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Previous studies have documented metabolic abnormalities in individuals with 
spinal muscular atrophy (SMA). This study investigated the impact of diet and fasting on 
blood glucose levels using a continuous blood glucose monitor (CGM) in conjunction 
with detailed food diaries in a small cohort (N=8) of children with SMA type II. Children 
ages 9 to 16 years, without any previous diabetes diagnoses or interventions, participated 
in the study. The study was completed in two parts; a one-time outpatient visit and a 4- 
day at-home portion. During the outpatient visit, fasting insulin, fasting glucose, and 
hemoglobin A1c (HgA1c) laboratory tests were obtained and the CGM was inserted. 
Anthropometric measurements including height, weight, triceps skin fold, and assessment 
of body composition using bioelectrical impedance analysis (BIA) were collected. 
Following the outpatient visit, participants tracked dietary intake and maintained the 
CGM for 4 days at home. For 1 day of the study, participants consumed a prescribed 
specialized diet comprised of 45.6% of total caloric intake from carbohydrates and 
adequate fiber intake (26.4g). Data analysis was both descriptive and exploratory. Seven 
of 8 participants were overfat according to BIA analysis. Although not statistically 
significant, blood glucose variation decreased 0.50 mg/dL for every gram of fiber 
consumed. Upon visual analysis, dietary intervention seemed to have a moderating effect 
on blood glucose levels of participants with varying metabolic control, as indicated by 




overfatness was common among participants and may correlate with blood glucose 
variability as BMI percentile increases. Implementing dietary recommendations for patients 
with SMA type II to increase daily fiber intake may prove beneficial for blood glucose 
regulation. Additionally, counseling to maintain adequate weight as assessed by both CDC 
BMI-for-age and body composition methods could improve patient blood glucose control in 
patients with SMA type II. Further research is required in order to determine significance of 
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Spinal muscular atrophy (SMA) is the most common genetic cause of death in 
infants with an incidence of 1 in 10,000 live births (1, 2). The autosomal recessive 
disease is caused by mutations or deletions within the survival motor neuron gene 
(SMN1) on chromosome 5q13.  Two genes on chromosome 5q13 are responsible for 
SMN protein production: SMN1, the telomeric copy of the gene, and SMN2, the 
centromeric copy of the gene. Due to a mutation or deletion, SMN1 can be rendered 
nonfunctioning. However, SMN protein production can be partially compensated for by 
the SMN2 gene. The severity of SMA is dependent on the number of functioning copies 
of SMN2 and the amount of SMN protein produced by these remaining genes. The 
disparity of SMN protein production leads to the degradation of α-motor neurons in the 
ventral horn of the spinal cord and brain stem nuclei, causing muscle atrophy and 
hypotonia. Variance in the amount and quality of SMN produced by SMN2, as well as 
other currently unknown modifying factors, allows for classification of SMA based on 
the highest motor milestone achieved (3).  
 SMA type I is the most commonly diagnosed form of SMA, comprising 50% of 
SMA diagnoses (1). Also known as Werdnig-Hoffman disease, SMA type I is the most 
severe form of SMA. Symptoms are present by 6 months of age and include inability to 
sit unaided and limited or inability to support the head. Other manifestations of SMA 





SMA type I has a survival rate of 18% past 4 years of age (5).  
SMA type II symptoms usually become apparent between 7 and 18 months of age 
with expected survival into adulthood. Individuals with SMA type II are able to sit 
unsupported at some point during their clinical course but are never able to walk unaided 
(1, 6). Presentations of SMA type II may include bulbar weakness, issues chewing and 
swallowing, and commonly development of contractures and scoliosis (1). Likewise, 
frequent falls and exercise intolerance are noted effects of SMA type II (5).  Additionally, 
individuals with SMA type II are at higher risk for respiratory infections due to 
insufficient clearance of mucus and secretions (4, 7).  
Individuals diagnosed with SMA type III, also named Kugelberg-Welander 
disease, are able to stand and walk unaided for at least a period of their lives. SMA type 
III is diagnosed after 18 months of age with life expectancy into adulthood (8). Effects of 
SMA type III may include scoliosis and respiratory issues (4). Muscle and joint issues are 
also reported in this group.  
Recently, there has been research suggesting a fourth sub-category of SMA, SMA 
type IV. SMA type IV is classified as adult onset SMA with diagnosis at 18 years of age 
or older, usually in the second or third decade of life. Individuals with SMA type IV have 
the ability to walk unaided at one point in their life (4, 8). Individuals with SMA type IV 
may also express minor motor impairment; however, they show few to no respiratory or 
gastrointestinal problems (4).  
 Aside from the manifestations of the disease, individuals with SMA experience a 
variety of associated symptoms that have detrimental nutritional and physical activity 





composition. Decreased lean muscle mass and disproportionately high fat mass may also 
play a role in the metabolic abnormalities seen in individuals with SMA. These 
abnormalities include metabolic acidosis, abnormal fatty acid metabolism, 
hyperlipidemia, hyperglycemia, and hypoglycemia when in a fasting state (9-11). 
Furthermore, these symptoms can be potentially traced to changes at the cellular level in 
individuals with SMA.  
To explore the metabolic effects of SMA more thoroughly, Bowerman et al. 
examined whether metabolic and pancreatic defects would be seen in SMN depleted 
mice. The SMN depleted mice (Smn+/-) did not present with phenotypic expression of 
SMA and produced approximately 50% of SMN protein in comparison to SMN 
production in wild type mice (10). The development of these mice may mimic less severe 
degrees of SMA in humans. Smn+/-  mice at 1 year were 15% to 20% heavier than wild 
type mice which may indicate a role of the SMN protein in weight control and 
metabolism (10). Additionally, these mice presented with higher fasting glucose levels 
and hyperinsulinemia at 1 year (10). 
 In another study conducted by Bowerman et al., metabolic deviations were 
observed in SMN protein limited mice (Smn2B/-), producing 15% of normal SMN protein 
quantities. Specifically, a temporal change in pancreatic composition from a normal ratio 
of insulin secreting β-cells to glucagon secreting α-cells to an abnormally low ratio of β- 
cell to α-cells in these mice was observed (12). Glucagon regulates gluconeogenesis; 
therefore, an abnormal increase of pancreatic α-cells may cause irregularities in 
gluconeogenesis and other metabolic processes. Similar pancreatic distributions were also 





Additionally, β-cell function is important in the pathogenesis of type II diabetes 
mellitus. In a study by Butler et al., a statistically significant decrease in β-cell volume 
was observed at autopsy in obese adults with impaired fasting glucose or type II diabetes 
mellitus when compared to obese nondiabetic adults. Although different from the 
Bowerman et al. findings, where change in β-cell volume was potentially due to a fate 
switch from  β-cell to α-cell characteristics, rather than increased apoptosis as found by 
Butler et al., both resulted in change of β-cell volume (13). Although different in 
pathology, the metabolic irregularities seen with changes in β-cell and α-cell volume 
further exemplify the effects of pancreatic alterations. 
Muscle mass also has an important role in gluconeogenesis during fasting. 
Orngreen et al. demonstrated that during a 23-hour fasting period, 13 study participants 
with neuromuscular diseases, including 4 with SMA, had higher rates of lipolysis and 
contribution of glycerol from free fatty acids to gluconeogenesis than healthy controls. 
Additionally, all participants with SMA became hypoglycemic during the fasting period. 
This finding is likely the result of a lack of contribution of gluconeogenic substrates from 
muscle stores due to decreased lean body mass compared to healthy controls (11).   
 Additionally, individuals with SMA are at risk of developing increased fat mass 
and decreased fat free mass in comparison to healthy peers (14), often described as being 
overfat, or alternatively, metabolically obese. In a study by Sproule et al., fat mass index 
(kg fat mass/m2) was found to be significantly increased in study participants with SMA, 
all types, compared to healthy children with consideration to age, race, and gender 
regardless of body mass index (BMI) (14). Additionally, a majority of the study 





overweight or obese in comparison to healthy peers (14).  
Furthermore, Poruk et al. found increased fat mass in infants with SMA type I 
was associated with age (15). Also, infants with a weight-for-age greater than the 90th 
percentile had significantly higher percent fat mass than those within the 50th to 70th 
percentiles (15). The study also inferred that although children with SMA may fall within 
the underweight to healthy BMI ranges for the healthy pediatric population, children with 
SMA may have  significantly higher fat mass than their peers (14, 15). Both of these 
studies demonstrate that individuals with SMA display an increase in fat mass and a 
decrease in fat free mass (14, 15). This trend was more extreme in participants with SMA 
type I and II and emphasizes the discrepancy between fat mass and BMI measurements in 
the SMA population (14).   
Excess fat, or obesity, during childhood is the most prominent determinant for 
insulin resistance, metabolic syndrome, and type II diabetes (16-18). To further evaluate 
this mechanism along with other metabolic events in the SMA population, Hurst et al. 
conducted a pilot study exploring body composition, response to fasting, and glucose 
tolerance in children with SMA type II. Six children, ages 7 to 11 years, participated in 
the study. All 6 study participants were classified as obese as evaluated by the National 
Health and Nutrition Survey (NHANES) smoothed body fat percentiles for body 
composition (18). However, when charted in accordance to Centers for Disease Control 
and Prevention (CDC) BMI-for-age growth charts, only 3 of 6 participants were found to 
be obese, and 2 to be overweight, emphasizing the inadequacy of using CDC BMI-for-
age percentiles as a measure of body composition for participants with SMA (18).  





were not consuming excessive amounts of carbohydrates or calories. However, 
participants on average only met half of recommended dietary fiber intake needs.  
The aforementioned study also explored glucose metabolism in children with 
SMA type II. Upon oral glucose tolerance testing, 3 of 6 participants met the American 
Diabetes Association’s guidelines for impaired glucose tolerance (18). Five of 6 
participants were insulin resistant as calculated by homeostatic model assessment for 
insulin resistance (HOMA-IR) during the supervised fast when compared to age- and 
gender-based guidelines (18). All participants exhibited hyperinsulinemia during fasting 
(18). Of note, hyperinsulinemia often anticipates glucose intolerance and may increase 
risk for type II diabetes in the future (19, 20). In summary, the pilot study indicated that 
SMA manifestations and progression may promote overfatness and affect glucose 
metabolism.  
The culmination of negative metabolic symptoms, namely overfatness, 
abnormalities in glucose metabolism, and hyperinsulinemia may further exacerbate the 
effects of SMA and potentially lead to diseases such as type II diabetes and metabolic 
syndrome. Further exploration of the effects of the SMN protein on metabolic function is 
needed. Investigation of the outcomes of nutritional intervention in children with SMA 
type II has become of interest to increase quality of life, lifespan, and further deduce the 
roles of SMN protein in the human body.   
The specific aims of this clinical study were to: 1) Monitor continuous blood 
glucose levels of 8 children with SMA type II 3 of whom have participated in a previous 
glucose tolerance and fasting study and have presented with hyperinsulinemia and; 2) 





participants under two conditions (typical diet and moderate carbohydrate/high-fiber). 
The hypothesis of this study was moderate carbohydrate intake in combination with 









Participant Selection Criteria 
The study enrolled 8 children diagnosed with SMA type II. The 6 children with 
SMA type II who previously participated in the pilot glucose study were recruited first. 
Due to limited response, additional children with SMA type II meeting inclusion criteria 
were recruited for a total of 8 participants enrolled. 
Inclusion criteria included genetic diagnosis with SMA 5q, clinical diagnosis of 
SMA type II, and age 6-18 years. Exclusion criteria included acute illness, use of feeding 
tube for more than 50% of caloric intake, inability to swallow safely, medical diagnosis 




 Children enrolled in the study were registered as outpatients in the University of 
Utah Center for Clinical and Translational Science (CCTS). During this visit, CGM 
devices were placed. The CGM devices were worn for 4 days at home. During these 4 
days, the primary caregivers recorded the dietary intake of the children in a food diary. 
On 1 of the 4 days, the children abided by a prescribed specialized diet. On the fifth day, 
the CGM devices were removed by the primary caregivers and returned to the research 





at the University of Utah.  
 
Study Design 
 The study was completed in two parts: an outpatient visit overseen by trained 
personnel and an at-home portion completed over 4 days. For the outpatient visit, written 
informed parental consent and assent were obtained for all participants. Baseline 
measurements were collected including anthropometric measurements (weight, height, 
triceps skin fold, mid-arm circumference), bioelectrical impedance analysis (BIA), and 
standard vital signs. After an overnight fast, blood samples were obtained upon admission 
for hemoglobin A1c (HgA1c), blood glucose, and insulin. Following standard 
procedures, blood samples were analyzed by Associated Regional and University 
Pathologists, Inc. Laboratories (ARUP, Salt Lake City, Utah). The CGM devices 
(Medtronic iPro CGM, Northridge, California) were then placed on the children. Verbal 
explanation of operation of the CGM and how to take fingersticks using the provided 
glucometer (FreeStyle Lite Blood Glucose Monitoring System, 2010, Abbott Diabetes 
Care Inc., Alameda, California) was given. Following placement of the CGM and review 
of instructions, directions concerning diet and maintaining food diaries were provided by 
trained personnel. The children were instructed to consume their regular diet for 3 out of 
the 4 study days and on 1 day, abide by the prescribed specialized diet. A meal plan, 
cooking instructions, and all nonperishable items used in the prescribed specialized diet 
were provided in order to keep the diet as homogenous as possible amongst the 
participants.  





study at home. Blood glucose values were automatically monitored by the CGM. All 
necessary blood glucose information was recorded by the device. Additionally, the 
participants recorded fingerstick glucometer values 3 to 4 times daily. These glucometer 
readings were used to ensure the CGM was properly calibrated. During the at-home 
portion, children followed their normal diet patterns for 3 of the 4 days and followed the 
prescribed specialized diet for 1 day. Primary caregivers completed food diaries 
documenting dietary intake for each day. After 4 days of tracking dietary intake and 
blood glucose monitoring, the CGM devices were removed and returned to the study 
office along with the completed food diaries.  
 
Continuous Blood Glucose Monitoring 
 The CGM data were uploaded to the computer and calibrated using recorded 
blood glucose fingersticks. Compiled data were then analyzed for associations between 
the food diaries and carbohydrate intake. Variation was defined as the range of blood 
glucose values during the specified day. 
 
Food Diary 
The primary caregivers were responsible for recording participant dietary intake 
for 4 days through the use of a food diary. The food diary included types and quantities of 
foods, liquids, vitamins, and other supplements consumed. The food diaries were 
analyzed using Food Processor (version 10.5.2, 2009, ESHA Research, Salem, Oregon) 
for total kilocalories, macronutrient, and micronutrient content. The prescribed 





from fat, 18.9% of calories from protein, and contained 26.4 grams of fiber. Adherence to 
the prescribed specialized diet was evaluated and noted.   
 
Anthropometric Measures 
 Anthropometric measurements were obtained by trained personnel during the 
outpatient visit using standard protocols (21). Weight was measured via a wheelchair 
accessible scale to the nearest tenth of a kilogram (Cardinal Scale Mfg. Co., Webb City, 
MO, kg). Height was evaluated through the use of segmental measures and arm span 
measures (standard, nonstretchable measuring tape, cm). Segmental measures included: 
head to shoulder, should to hip, hip to knee, knee to ankle, and ankle to heel. Ulnar 
measurements, chest circumference, and waist circumference were taken with a non-
stretchable measuring tape (standard, nonstretchable measuring tape, cm). Triceps skin 
fold (Lange Skinfold Caliper, Cambridge, Maryland, mm) and mid-arm circumference 
(standard nonstretchable measuring tape, cm) were also assessed. All measurements were 
obtained from the right side of the body.  
 Weight status was determined using CDC BMI-for-age growth charts. Weight 
categorized between the 85th and 95th percentile was defined as overweight; weight 
categorized as the 95th percentile or above was defined as obese. 
 
Bioelectrical Impedance Analysis 
 Body composition was measured using a bioelectrical impedance analysis 
machine (RJL Quantum Bioelectric Impedance Analyzer, Clinton Township, MI). 





attached to their hands and feet. The current was sent through the body and the machine 
completed the process of measuring and calculating resistance. Recorded data were 
uploaded to the associated software (RJL Systems BC (Body Composition) Version 
3.0.9, Clinton Township, Michigan). The software was then used to calculate fat mass 
percentage and fat free mass percentage per software automated pediatric equation. Body 
fat percentiles were assessed using smoothed body fat percentiles generated from data 
collected from NHANES dual energy x-ray absorptiometry (DXA) measurements of 
children ages 8-19 years (22). 
 
HOMA-IR 
Insulin resistance was determined using HOMA-IR calculations: [fasting glucose 
(mg/dL)(fasting insulin(μIU/mL))]/405 (23). Cut off values for insulin resistance were 
defined as ≥ 2.67 and ≥ 2.22 for prepubertal males and females, respectively; and  ≥ 5.22 
and ≥ 3.82 were used for pubertal males and females, respectively (23).   
 
Statistical Analysis 
 Blood glucose levels taken by the CGM were compared to the recorded food 
diaries. Marked increases, decreases, relations, and patterns were noted. Blood glucose 
patterns observed during the prescribed specialized diet day were compared to the 
glucose patterns seen during the nonspecialized diet days as reported by the CGM.  
 The difference between the variations of participant blood glucose during the 
prescribed specialized diet day and the average variation in blood glucose over the 3 





We noted the effects of the prescribed specialized diet day on blood glucose variation in 
comparison to the blood glucose variation during nonspecialized days. Additionally, the 
blood glucose response to food intake was evaluated by comparison of the food diaries 
and the CGM data.  
 Association between amount of fiber (in grams) consumed per day and variation 
in blood glucose per nonspecialized diet days was assessed using a linear mixed model. 
Pearson correlation tests were used to evaluate the associations between the following 
variables: 1) BMI percentile and variation in blood glucose on regular diet days; 2) 
Calories from carbohydrate and HOMA-IR; 3) Average percent of daily fiber 
recommendation intake during nonspecialized diet days and HOMA-IR; 4) Fat mass 
percentage and variation in blood glucose; 5) Fat mass percentage and HOMA-IR; 6) 
Correlation between fat free mass percentage and HOMA-IR. All analyses were 
performed with Statistical Analysis Software (version 9.4, SAS Institute Inc., 2013, Cary, 






Eight children participated in the study; 3 females and 5 males. The mean age of 
participants was 12.1 ± 2.4 years (range 9-16 years). Within the participant population, 1 
self-identified as black and 7 self-identified as Caucasian. Additionally, 3 children 
identified as Hispanic, 4 identified as non-Hispanic, and 1 participant did not specify 
ethnicity. All 8 children participated in the hospital portion of the study, completed the at-
home segment, and returned the CGM to the study office along with completed food 
diaries.  
 
Continuous Blood Glucose Monitoring 
Within the group, per every 1 gram of fiber intake, blood glucose variation 
decreased by 0.50 mg/dL; however, this result did not reach statistical significance 
(p=0.22). Additionally, with every 1% increase of calories from carbohydrate, blood 
glucose variation increased by 0.073 mg/dL. This result did not reach statistical 
significance (p=0.76). 
  BMI percentile and variation in blood glucose on nonspecialized diet days had a 
moderate correlation; however, the association was not statistically significant (r=0.55, 
p=0.15). Within group, the correlation between fat mass percentage and variation in 





low body fat in comparison to the study population was excluded from this analysis. 
 Figure 1 depicts the difference in blood glucose variation observed from the 
average of nonspecialized diet days to the prescribed specialized diet day for all 
participants. Participant H was excluded due to digression from protocol. Additionally, 
Figures 2 and 3 depict differences in blood glucose variation for participants B and C on 
a day-by-day basis.  
 
Food Diary 
 All 8 participants completed food diaries, with documentation of 3 days of regular 
diet patterns and 1 day of the prescribed specialized diet day. As a group, on average, the 
nonspecialized diet days were comprised of 50.5 ± 23.4%  calories from carbohydrate, 
33.3% ± 12.0% calories from fat, and 16.6% ± 5.3% calories from protein. Additionally, 
average grams consumed during the nonspecialized diet days were 195.5 ± 90.4g 
carbohydrate (range: 106.7g-393.0g), 56.8g ± 20.6g (range: 29.7g-97.3g) fat, and 64.3g ± 
20.6g (range: 40.7g-91.7) protein. During the nonspecialized diet days, the percent of 
recommended grams of fiber consumption met was 52.1% ± 17.5% (range: 28.7%-
64.4%) and the average of grams of fiber was 12.6g ± 4.7g (range: 7.1g-21.3g). Table 1 
reports the group average calorie and macronutrient intake and percent of caloric intake 
during the nonspecialized diet days in comparison to the prescribed specialized diet.  
 
Anthropometric Measurements and Bioelectrical Impedance Analysis 
BMI, BMI classification, and BIA results are stated in Table 2. According to the 





obese. Average fat mass percentage was 53.0% ± 8.9% (range: 32.3%-62.6%). Average 
fat free mass percentage was 47.1% ± 8.9% (range: 37.4%-67.7%). 
 
HOMA-IR 
HOMA-IR calculation results are stated in Table 2. Two of 8 participants were 
found to be insulin resistant based on HOMA-IR calculations. No significant correlation 
was found between the percent of calories from carbohydrate and HOMA-IR nor between 
the average grams of fiber intake during nonspecialized diet days and HOMA-IR (r=0.15, 
p= 0.72 and r=0.19, p=0.65, respectively). Significant associations were not found 
between fat mass percentage and HOMA-IR (r=0.14, p=0.75,) nor between fat free mass 



















Figure 1. Data represent the difference in variation of blood glucose from average of 
nonspecialized diet days to prescribed specialized diet day.  











































Figure 2. Data represent the change in variation of blood glucose day-by-day for 





































Figure 3. Data represent the change in variation of blood glucose day-by-day for 







































Table 1. Comparison of group average calorie and macronutrient intake and percent of 














Calories (kcal) 1548 ± 589.8 - 1196 - 
Carbohydrate 
(g) 195.5 ± 90.4 50.5% ± 23.4% 138 45.6% 
Fat (g) 56.8 ± 20.6 33.0% ± 12.0% 48 35.5% 
Protein (g) 64.3 ± 20.6 16.6% ± 5.3% 57 18.8% 
















Table 2. Body composition data and HOMA-IR calculation results.  
*Bold denotes out of normal reference range 
† HOMA-IR cut off values are determined for obese children (>95%ile for BMI-for-age) 
(23)  
‡ Denotes pre-pubertal status 
Participant Fat Mass % 










A 53.7 46.3 23.8 88 1.15 3.12 
B 62.6 37.4 22.6 66 0.41 1.7 
C 55.6 44.4 26.7 99 2.24 10‡ 
D 52.3 47.7 20.7 94 1.52 6.5‡ 
E 32.3 67.7 11.1 0 -7.4 2.5 
F 55.7 44.3 23.7 93 1.49 3.6 
G 53.6 46.5 17.7 24 -0.71 3.3 
H 57.8 42.2 24 96 1.77 4.5 
 




  Male† Female† 
Pre-pubertal  2.67 2.22 







 As a prospective exploratory study, we were able to investigate the metabolic 
response of children with SMA type II to varying glucose loads and fiber intake over a 
short period of time. Unique findings include the decrease in blood glucose variation seen 
with increased fiber intake, the potential of dietary intervention having influence in 
children with a wide range of metabolic control, impaired blood glucose control with 
increased BMI percentile classification, and the consistency of overfatness in children 
with SMA type II despite normal BMI-for-age percentiles.  
 Although not statistically significant, the results indicate that an increased fiber 
load decreases variation in blood glucose in the participants studied. As reported, per 
every 1 gram of fiber intake, blood glucose variation decreased by 0.50 mg/dL. On the 
prescribed specialized diet day, participants, if protocol was followed, consumed 26 
grams of fiber, meeting the RDA for the majority of our participant population. This 
amount contrasted vastly from observed intake during the nonspecialized diet days, 
ranging from 3 grams to 26 grams per day. On average, the participants met only 52% of 
recommended fiber intake, analogous to the findings of Hurst et al. in which participants 
were only consuming approximately one-half of recommended dietary fiber as reported 
by food diaries. To date, limited studies have been conducted on the effects of fiber 
intake on body weight in the pediatric population, with minimal research specific to the 





relation to risk for overweight or obese status in the pediatric population. Study results 
indicated there was a significant decrease in risk of overweight/obesity status with 
increasing fiber intake in children ages 12 to 18, a similar age range as the participant 
population in this study (24).  Moreover, for the current study, fiber intake during the 
prescribed specialized diet day was even higher than the highest tertile as reported by 
Brauchla et al., leaving potential for an even greater impact in individuals with SMA, 
especially if long term.    
 Another outcome of interest is the visual result that dietary intervention seems to 
have an impact on participants with varying metabolic control, as evaluated by HOMA-
IR scores. Depicted in Figure 1, participants B and C had a notable decrease in blood 
glucose variation from the average of nonspecialized diet days in comparison to the 
prescribed specialized diet day. For participant C, lab values were indicative of insulin 
resistance as assessed by HOMA-IR, whereas lab values of participant B were not. As 
exemplified by the benefits shown in blood glucose control by both participants B and C, 
despite differing classification of insulin resistance, children with a wide spectrum of 
metabolic control and diagnosis of SMA may benefit from dietary intervention.  
 Additionally, although not statistically significant, results indicate blood glucose 
variation had a moderate correlation with BMI percentile on nonspecialized diet days. 
Therefore, study participants with increased BMI percentiles potentially had greater 
variation of blood glucose levels, indicating reduced blood glucose control.  Specifically, 
the BMI percentiles of 5 of 8 participants were greater than the 85th percentile, classifying 
them as obese or overweight. Moreover, impaired blood glucose is an associated 





type II diabetes mellitus. In these disease states, impaired blood glucose control may be 
evidenced by or prefaced by hyperinsulinemia and glucose intolerance (19, 20). This 
finding suggests blood glucose control in individuals with SMA type II may benefit from 
maintaining appropriate weight status.  
 Likewise, overfatness was prevalent among our participants, with the exception of 
1 cachectic participant. As previously discussed, overfatness is an abnormal ratio of fat 
mass to fat free mass and is commonly seen in children with SMA when compared to 
healthy cohorts (14). When plotted according to NHANES smoothed body fat 
percentiles, 7 of 8 participants were classified above the 95%ile, the cut-off point for 
obesity, whereas when plotted according to CDC BMI-for-age charts, only 4 of 8 can be 
identified as obese and 1 participant as overweight. These results were also reflected in 
the findings of Hurst et al., where 6 of 6 participants were considered obese following 
DXA-determined body mass percentage and plotting on NHANES smoothed body fat 
percentiles, whereas only 3 participants identified as obese and 2 as overweight according 
to CDC BMI-for-age charts. Conclusively, this evidence further demonstrates BMI-for-
age percentiles from CDC growth charts do not correlate with body composition for 
children with SMA. With this in mind, health professionals need to be aware that children 
with SMA type II are at higher risk for metabolic issues at a lower BMI due to 
differences in body composition compared to healthy peers.  For example, children may 
have a normal BMI-for-age, yet their risk for metabolic-related issues may be increased. 
Use of body composition estimations, such as BIA or DXA, in addition to anthropometric 
measures, provides a more comprehensive assessment of metabolic health than 





Moreover, the incongruity of these measurement tools emphasizes the underlying 
idea that health professionals must stress the importance of weight control and tracking in 
children with SMA in order to proactively address issues and avoid complications of 
excess fat mass and obesity. These risks may be mitigated if children with SMA are able 
to work closely with a dietitian in order to address decreasing caloric need with loss of 
fat-free mass, decreased motor abilities, and other associated nutritional changes. 
 As a prospective exploratory study, our experimental design was simple and 
efficient.  The CGM gathered comparable valid blood glucose information from each 
participant. These data had a strong correlation to actual blood glucose levels via 
information provided by daily fingersticks.  
The study increased homogeneity of ingredients used during the prescribed 
specialized diet day by providing all nonperishables. Although we were not able to 
provide all foods due to cost and travel arrangements, we provided written and verbal 
instructions on preparation and provided a detailed menu. By giving discrete instructions 
and providing specified foods, we enabled the participants to consume as close to an 
identical diet for the prescribed specialized diet day, permitting for the most comparable 
data.  
The design of our study does not greatly impede the daily life of the participant, 
increasing validity and insight into the day-to-day life and dietary patterns of a person 
living with SMA type II. The study had little participant responsibility aside from 
recording daily food intake and blood glucose fingersticks. The CGM allowed for data 
collection with few participant obligations and increased the validity of data collected. 





which requires participants to submit daily food diaries. Therefore, recording dietary 
intake may not be seen as an additional obligation of the study.   
 Despite a strong study design, there are limitations. Our study relied on 
participant compliance to complete and return detailed daily food diaries to compare 
against the data collected by the CGM. Upon analysis using the ESHA software, some 
food diaries did not provide sufficient information to appropriately enter foods consumed 
and had to be estimated for brand, type, cooking style, and/or amount. These estimations 
may have altered the observed relationships between the blood glucose levels and dietary 
intake. 
 Due to limitations of the battery life of the CGM, participants had to complete all 
aspects of the study within 10 days. Therefore, the timespan of our intervention was 
limited and unfortunately only feasible for a single day. Long-term dietary interventions 
could have a more pronounced effect on health status and metabolic measures. The short- 
term effects seen, particularly with fiber intake, have potential to be more dramatic if 
practiced for a longer period of time.  
Additionally, the blood glucose values of the nonspecialized diet days were 
evaluated as an average taken over 3 days, reducing the amplitude of blood glucose highs 
and lows experienced. This analysis could have potentially diminished the effects of the 
prescribed specialized diet day when compared. Therefore, the change seen during the 
prescribed specialized diet day, although not investigated for significance due to the 
small n, could have proven to have a greater impact if compared individually day-by-day 
to the nonspecialized diet days rather than as an average of the 3. Evaluation day-by-day 





 Our data also relied on the function and reporting of the CGM. For 1 participant, 
the CGM was at times unable to draw the necessary sample of blood; therefore, there 
were periods of time where no blood glucose values were reported. These time periods 
were removed from analysis. 
 The prescribed specialized diet day was designed to meet macronutrient intake 
needs and 75% of dietary recommended intake (DRI) for micronutrients. Personal 
experience with the tastes of the participant population encouraged us to choose pulp-free 
orange juice, a product with high naturally occurring sugars without notable fiber content, 
in place of milk to fulfill calcium and vitamin D requirements. As suspected, a notable 
spike in blood glucose followed by a greater drop was seen in participants following 
consumption of the juice. This blood glucose spike and decline may have mitigated the 
blood glucose control of the prescribed specialized diet day.  
 Another consideration for data analysis was that participant E was on overnight 
enteral feeds that consisted of a high carbohydrate, very low fat formula. This regimen 
resulted in blood glucose fluctuations overnight that were not seen in the rest of the study 
population and therefore may have mitigated the hypothesized control of the prescribed 
specialized diet day in the case of this participant. 
 Additionally, digression from protocol by a participant reduced sample size for 
the evaluation of the effects of the prescribed specialized diet day. Specifically, 
participant H was not compliant with protocol by consuming the prescribed specialized 
diet day meals over 2 days instead of 1 and did not completely abide by the prescribed 
food list. The second day, when the prescribed specialized diet was more thoroughly 





was removed from Figure 1 due to these deviations.  
 Availability of laboratory results of blood draws was another limitation of our 
data analysis. HgA1c values for 1 participant were lost by the lab during testing. The 
participant did not complete this lab test outside of their appointment as recommended; 
therefore, only 7 data points were available for analysis concerning HgA1c.  
 Evaluation of insulin resistance using HOMA-IR scores can also be somewhat 
variable. Considering that scores are based on fasting insulin and fasting glucose levels, 
marked changes in these values can occur in a relatively short period of time, effecting 
HOMA-IR evaluation. For instance, in the study by Hurst et al., participants were tested 
twice for insulin resistance via HOMA-IR scores within 8 weeks. During the first visit, 4 
of 6 participants were identified as insulin resistant, whereas at the second visit, 5 of 6 
participants met the criteria. Additionally, HOMA-IR scores can be dependent on the 
judgment of the clinician as to whether or not the child is pre-pubertal. Dependent on this 
maturity classification, cut off values for HOMA-IR classification vary. 
 Additionally, our investigation focused on a small study population of 8 
participants. The small population improved interpersonal care given to improve 
adherence to procedures and homogeneity. However, the limited number of participants 
decreased the strength of our analysis because the SMA type II population is very 
heterogeneous in terms of weight, mobility, respiratory function, and overall health 
status. Therefore, the small number of participants may not correlate with the breadth of 
the SMA type II population and limits the generalizability of the study.  
Although dietary changes may improve blood glucose control, SMA disease 





However, the difference contributed by diet, as exemplified by this intervention, may 
provide a basis for further studies and clinical treatment of metabolic issues in individuals 






 The outcomes of this study have the potential to elucidate associations between 
glycemic control, body composition, and SMA type II. The promising effects of 
improved glycemic control through increased fiber intake may be of interest for further 
studies and development of dietary interventions for SMA therapy. Likewise, outcomes 
of dietary intervention may have impact on participants with varying metabolic function 
and potentially be more significant if conducted for a longer period of time. Additionally, 
overfatness was common among participants and may correlate with impaired blood 
glucose control as BMI percentile increases. Lastly, body composition findings 
emphasize the inadequacies of using the CDC BMI-for-age growth charts to define 
overweight or obese status in children with SMA type II as well as the differences in 
body composition of children with SMA in comparison to healthy peers. Further 
investigation of extended dietary intervention influence and long-term metabolic changes 
in individuals with SMA type II is needed to determine relevance and effectiveness.  
Overall, the outcomes of this study elicit further investigation and awareness of 





































Child’s name: ________________________________________________________ 
 
Name of the caregiver(s) completing this form: _____________________________ 
 









My child’s feeds are: 
___All by mouth  
___By mouth and by feeding tube  
___Restricted to feeding tube only 
 
Please return this form to: 
 
Rebecca Hurst Davis 
Clinical Dietitian 
Department of Neurology 
University of Utah School of Medicine: 
30 N. 1900 E, Room 3R149 
Salt Lake City, Utah 84132 
FAX: 801-587-9346  
EMAIL: rhurst@genetics.utah.edu 
 




     
Nutritional Care Guidelines for children with SMA and other neuromuscular disorders 





DIRECTIONS FOR KEEPING THIS FOOD 
DIARY: 
Please record everything your child eats or drinks over a four day period, including the 
specialized diet day. This record should include feeds and supplements and all water or 
other liquids given via mouth, nasogastric, nasojejunal or gastrostomy tube. At the top of 
the page make sure to note the date and check the box of which day of the food record 
you are recording (Day 1, Day 2, Day 3, Day 4). 
 
1. Record all food and drink whether eaten/given at home or away from home. 
2. Be as specific as possible in recording the item, use a brand name if available. 
3. Measure the item when possible or estimate the amount using the pictures provided 
with this document.  
You can record in cubic centimeters (cc) or ounces (oz) with regard to liquids, and either 
ounces (oz) or grams (g) for food items. 
4. Please mention how the food was prepared (fried, boiled, baked, microwaved, etc.) and 
record items used in the preparation, including oil, margarine or butter, for instance. 
5. Don’t forget to include all condiments, such as ketchup, gravy, sauce, butter or oil, and 
record amounts as accurately as possible. For instance, you might record 2 french fries 
with 1 teaspoon ketchup. 
6. Please include one item per line where possible. 
7. Please include all supplements (vitamins) given, with brand names and labels if 
possible. 
8. You can use abbreviations for measurements: 
 Teaspoon – tsp          ¼ cup – ¼ C    Tablespoon – Tbsp             Ounce – oz 
 
9. Record blood glucose reading from glucometer finger stick in the “BG Value” column 
of the Food Diary. Finger sticks should be done 3-4 times daily. Suggested times for this 
are: before breakfast, before lunch, before dinner and at bedtime. Fingerstick glucose 
readings must be within 12 hours of each other.   
10. In the exercise column please note any exercise completed. In the duration column, 





Food, Formula, or Fluid and Amount (include preparation 
details) 
Exercise Duration 
7:00am 100    
7:30 am  ½ c 2% milk    
  ½ c Honey Nut Cheerios   
  1 medium banana   
























GUIDELINES FOR AMOUNTS OF WHOLE FOODS: 
 
 
     
            
1 teaspoon = the tip of an adult 
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